PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 4.94 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-03-04
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-03-31 was 1.90M shares, a 45.36% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-12-31 was 333.90K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-09-30 was 382.99K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-06-30 was 492.28K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 4.94M shares, a 44.81% increase from fiscal 2023.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 3.41M shares, a 48.42% decline from fiscal 2022.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 6.61M shares, a 66.03% increase from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2021 was 3.98M shares, a 14.92% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.94M shares 10-K · filed 2025-03-04 | |||
| 2023-12-31 | 3.41M shares 10-K · filed 2024-03-04 | |||
| 2022-12-31 | 6.61M shares 10-K · filed 2023-03-06 | |||
| 2021-12-31 | 3.98M shares 10-K · filed 2022-03-03 | |||
| 2021-03-31 | 1.90M shares 10-Q · filed 2021-05-05 | 2.23M shares derived: sum of 2 quarters · filed 2021-05-05 | 2.61M shares derived: sum of 3 quarters · filed 2021-05-05 | 3.11M shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 333.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | 716.89K shares derived: sum of 2 quarters · filed 2021-03-03 | 1.21M shares derived: sum of 3 quarters · filed 2021-03-03 | 4.68M shares 10-K · filed 2021-03-03 |
| 2020-09-30 | 382.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 875.27K shares derived: sum of 2 quarters · filed 2020-11-10 | 4.35M shares 10-Q · filed 2020-11-10 | |
| 2020-06-30 | 492.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 3.96M shares 10-Q · filed 2020-08-13 | ||
| 2020-03-31 | 3.47M shares 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | 3.69M shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |